Europe Surgical Site Infection Control Market Growth Prospects 2024-2032
Triton’s analysis suggests that the Europe surgical site infection control market is estimated to progress in terms of revenue at a CAGR of 5.16% during the 2024-2032 forecast period.
The surgical site infection control market in Europe has been experiencing significant growth owing to increased awareness and stringent regulations around infection prevention. The European Centre for Disease Prevention and Control (ECDC) reports that the occurrence of surgical site infections (SSIs) ranged from 0.6% in knee prosthesis surgeries to 9.5% in open colon surgeries, depending on the type of procedure. The ECDC’s report also highlighted that European healthcare systems have been focusing on enhancing infection control measures, supported by initiatives such as the ‘Joint Action on Antimicrobial Resistance and Healthcare-Associated Infections (EU-JAMRAI),’ which promotes best practices across EU member states.
The countries reviewed in this region comprise Germany, the Netherlands, France, Spain, Italy, the United Kingdom, and Rest of Europe.
The United Kingdom leads with the major market share, obtaining around $265.6 million in 2023
In 17 different surgical categories,1,122 surgical site infections were identified during the hospital stay or upon readmission during 2022-2023, as per a report by the UK Health Security Agency. The UK has seen a concerted effort to reduce these infections, given their association with prolonged hospital stays, increased morbidity, and higher healthcare costs. These concerns drive the demand for better infection control measures, thereby contributing to the market’s growth.The National Health Service (NHS) and related bodies have increased funding for research into infection control technologies, including advanced wound dressings, antiseptic solutions, and surgical techniques. This pushes healthcare providers to adopt advanced SSI control products and technologies, fueling market development.Market Forecast for Germany
The surgical site infection control market in Germany is supported by increasing awareness and stringent regulations aimed at reducing healthcare-associated infections. The nation has seen an uptick in demand for advanced infection control products, such as antimicrobial dressings, sterilization equipment, and infection-resistant surgical tools. The German Society for Hospital Hygiene has been instrumental in promoting best practices for infection prevention. This focus on infection control is reflected in the German healthcare sector’s increased investment in modern technologies and training programs designed to minimize the risk of SSIs, enhancing overall patient safety and surgical outcomes.
The market is branched into type of infection, procedure, industry vertical, and product. Based on the type of infection, it is divided into superficial, deep incisional, and organ or space SSI.
Surgical site infections (SSIs) are a common complication in gastrointestinal surgeries, particularly influenced by the type of surgery and wound closure methods used. Among these, superficial incisional SSIs are the most frequent, occurring at the incision site on the skin and often leading to pus formation. They can be classified into two types: primary, which occurs at the main incision site, such as in a C-section, and secondary, which arises at an additional incision site, like a donor site in coronary artery bypass graft surgery.
Contender Analysis in the Surgical Site Infection Control Market:
BioMérieux SA offers a range of solutions and products for diagnosing and managing infectious diseases, cardiovascular conditions, and specific cancers. Its services also include microbial flora analysis, detection of pathogenic bacteria, air and surface quality monitoring, etc. In the healthcare sector, it supports medical clinics, hospitals, pharmaceutical companies, dental and orthodontic professionals, and health information systems. The company operates through subsidiaries and an extensive network of distributors. It is headquartered in Marcy l’Étoile, France.
In January 2024, the company acquired LUMED, a software firm specializing in clinical decision support systems. LUMED’s technology assists hospitals in optimizing antimicrobial prescriptions and tracking healthcare-associated infections.
Other major companies in the market are 3M, Ansell Limited, Johnson & Johnson, Kimberly-Clark Corporation, and Stryker Corporation.
EUROPE SURGICAL SITE INFECTION CONTROL MARKET 2024-2032.pdf